li001

A new Weill Cornell Medicine study suggests a promising approach to stop the spread of Triple-Negative Breast Cancer (TNBC), one of the most aggressive cancer forms. Researchers found that the enzyme EZH2 drives TNBC cells to divide abnormally, leading to chromosomal instability and enabling them to metastasize (spread to distant organs). The study, published in Cancer Discovery, found that drugs […]

A study from Montefiore Einstein Comprehensive Cancer Center in Nature Neuroscience reveals that glioblastoma (GBM) is not just a local brain tumor but a systemic disease affecting the skull and immune system. GBM causes skull thinning, enlarging channels between the skull marrow and brain. This remodeling shifts immune balance—doubling pro-inflammatory neutrophils and nearly eliminating B cells—allowing

Sarcomas, a rare and aggressive category of over 100 connective tissue malignancies, present a significant challenge due to high metastasis rates and resistance to standard therapies like conventional chemotherapy and first-generation checkpoint inhibitors. A major breakthrough is occurring with Adoptive Cell Therapy (ACT), where a patient’s immune cells are genetically engineered to target cancer. Notably, the

Researchers at Duke University found that blocking a key enzyme not only kills multiple myeloma (MM) cancer cells but also boosts the effectiveness of existing therapies. MM is an incurable blood cancer, and drug resistance is an increasing problem. The study, published in Blood, focused on ferroptosis, a natural form of cell death triggered by